HIV-1 genotypic susceptibility scores (GSSs) were proven to be significant prognostic factors of fixed time-point virologic outcomes after combination antiretroviral therapy (cART) switch/initiation. However, their relative-hazard for the time to virologic failure has not been thoroughly investigated, and an expert system that is able to predict how long a new cART regimen will remain effective has never been designed.
Prosperi, M., Di Giambenedetto, S., Fanti, I., Meini, G., Bruzzone, B., Callegaro, A., Penco, G., Bagnarelli, P., Micheli, V., Paolini, E., Di Biagio, A., Ghisetti, V., Di Pietro, M. L., Zazzi, M., De Luca, A., A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen, <<BMC MEDICAL INFORMATICS AND DECISION MAKING>>, 2011; 11 (Giugno): 40-40. [doi:10.1186/1472-6947-11-40] [http://hdl.handle.net/10807/6351]
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen
Di Giambenedetto, Simona;Fanti, Iuri;Di Pietro, Maria Luisa;De Luca, Andrea
2011
Abstract
HIV-1 genotypic susceptibility scores (GSSs) were proven to be significant prognostic factors of fixed time-point virologic outcomes after combination antiretroviral therapy (cART) switch/initiation. However, their relative-hazard for the time to virologic failure has not been thoroughly investigated, and an expert system that is able to predict how long a new cART regimen will remain effective has never been designed.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
